Abstract:ENT‐03, a spermine bile acid we recently discovered in the brain of newborn mice acts centrally to regulate energy and metabolism. Obese, diabetic (ob/ob) mice treated with five doses of ENT‐03 over 2 weeks, demonstrated a rapid decrease in blood glucose levels into the range seen in non‐obese animals, prior to any significant weight loss. Weight fell substantially thereafter as food intake decreased, and serum biochemical parameters normalized compared with both vehicle and pair‐fed controls. To determine whether ENT‐03 could be acting centrally, we injected a single dose of ENT‐03 intracerebroventricularly to Sprague–Dawley rats. Weight fell significantly and remained below vehicle injected controls for an extended period. By autoradiography, ENT‐03 localized to the arcuate nucleus of the hypothalamus, the choroid plexus and cerebrospinal fluid. Significant cFos activation occurred in multiple anatomical regions within the hypothalamus and brainstem involved in appetite suppression, food‐entrained circadian rhythmicity, autonomic function, and growth. These data support a role for ENT‐03 in the treatment of type 2 diabetes and obesity. Phase 1 studies in subjects with obesity and diabetes are currently in progress.

A novel, centrally acting mammalian aminosterol, ENT‐03, induces weight loss in obese and lean rodents